Leap therapeutics, inc. (LPTX)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16
Assets
Current assets:
Cash and cash equivalents

25,465

3,891

10,058

15,747

21,709

16,284

23,249

30,481

35,376

25,737

14,203

17,171

23,800

793

Research and development incentive receivable

-

-

-

-

-

836

-

-

-

-

-

-

-

-

Research and development incentive receivable

247

185

752

836

844

-

937

959

998

1,744

1,894

3,170

3,167

3,053

Prepaid expenses and other current assets

272

165

210

211

159

202

191

608

289

177

404

382

319

183

Total current assets

25,984

4,241

11,020

16,794

22,712

17,322

24,377

32,048

36,663

27,658

16,501

20,723

27,286

4,029

Property and equipment, net

114

124

149

161

74

86

98

111

123

135

148

160

159

119

Right of use assets, net

835

1,026

1,214

1,398

1,578

-

-

-

-

-

-

-

-

-

Deferred tax assets

112

127

-

-

-

124

-

-

-

-

-

-

-

-

Deferred costs

623

831

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs

623

831

-

-

-

162

-

-

-

-

-

-

-

-

Deposits

1,074

1,099

-

-

-

1,380

-

-

-

-

-

-

-

-

Research and development incentive receivable, net of current portion

-

-

177

135

74

-

1,131

851

632

-

-

906

397

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

1,402

Deferred tax assets

-

-

120

124

126

-

147

151

157

158

-

-

-

-

Other assets

-

-

1,461

1,525

1,519

-

1,373

1,246

1,111

1,111

930

937

937

907

Total assets

28,742

7,448

14,141

20,137

26,083

19,074

27,126

34,407

38,686

29,062

17,579

22,726

28,779

6,457

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

4,933

4,571

4,889

5,325

3,298

3,579

4,149

4,766

4,130

2,622

2,598

3,088

2,793

3,225

Accrued expenses

2,387

3,441

2,317

2,474

4,150

2,872

1,897

1,261

1,715

3,461

3,396

1,287

1,819

2,658

Deferred revenue - current portion

1,500

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted stock liability

-

-

159

-

-

-

-

-

-

-

-

-

-

-

Lease liability - current portion

379

474

566

657

738

-

-

-

-

-

-

-

-

-

Notes payable and accrued interest - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

30,274

Total current liabilities

9,199

8,486

7,931

8,456

8,186

6,451

6,046

6,027

5,845

6,083

5,994

4,375

4,612

36,157

Non current liabilities:
Warrant liability

-

-

-

-

-

3,448

14,452

16,245

16,713

11,862

-

-

-

-

Restricted stock liability

-

159

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue, net of current portion

1,125

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liability, net of current portion

454

552

648

742

833

-

-

-

-

-

-

-

-

-

Total liabilities

10,778

9,197

8,579

9,198

9,019

9,899

20,498

22,272

22,558

17,945

-

-

-

36,157

Commitments and contingencies (Note 9)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

Stockholders' equity (deficiency):
Common stock, $0.001 par value; 100,000,000 shares authorized; 35,799,488 and 24,194,877 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

36

24

24

23

22

15

15

15

15

12

9

9

9

-

Additional paid-in capital

219,642

193,319

192,383

189,831

187,635

162,393

161,468

160,522

157,290

141,770

135,649

135,000

134,347

145

Accumulated other comprehensive loss

988

76

327

322

278

302

160

-19

-158

-268

-269

331

-105

294

Accumulated deficit

-202,702

-195,168

-187,172

-179,237

-170,871

-153,535

-155,015

-148,383

-141,019

-130,397

-123,804

-116,989

-110,084

-100,670

Total stockholders' equity (deficiency)

17,964

-1,749

5,562

10,939

17,064

9,175

6,628

12,135

16,128

11,117

11,585

18,351

24,167

-100,231

Total liabilities and stockholders' equity (deficiency)

28,742

7,448

14,141

20,137

26,083

19,074

27,126

34,407

38,686

29,062

17,579

22,726

28,779

6,457